Advanced search
Publication Cover
Infectious Diseases Volume 54, 2022 - Issue 6
Submit an article Journal homepage
228
Views
10
CrossRef citations to date
0
Altmetric
Original Articles

SARS-CoV-2 seroprevalence in Portugal following the third epidemic wave: results of the second National Serological Survey (ISN2COVID-19)

Irina Kislayaa Departamento de Epidemiologia, Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, PortugalCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-5772-2416
ORCID Icon,
Paulo Gonçalvesb Departamento de Doenças Infeciosas, Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, PortugalORCID Iconhttps://orcid.org/0000-0002-4633-6306
ORCID Icon,
Verónica Gómeza Departamento de Epidemiologia, Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, PortugalORCID Iconhttps://orcid.org/0000-0003-0485-0005
ORCID Icon,
Vânia Gaioa Departamento de Epidemiologia, Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, PortugalORCID Iconhttps://orcid.org/0000-0001-7626-4991
ORCID Icon,
Rita Roquettea Departamento de Epidemiologia, Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, PortugalORCID Iconhttps://orcid.org/0000-0003-2482-8956
ORCID Icon,
Marta Barretoa Departamento de Epidemiologia, Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, PortugalORCID Iconhttps://orcid.org/0000-0001-6464-548X
ORCID Icon,
Mafalda Sousa-Uvaa Departamento de Epidemiologia, Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, PortugalORCID Iconhttps://orcid.org/0000-0002-7910-3111
ORCID Icon,
Ana Rita Torresa Departamento de Epidemiologia, Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, PortugalORCID Iconhttps://orcid.org/0000-0003-0486-647X
ORCID Icon,
Joana Santosa Departamento de Epidemiologia, Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, PortugalORCID Iconhttps://orcid.org/0000-0001-8888-7854
ORCID Icon,
Rita Matosb Departamento de Doenças Infeciosas, Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, Portugal
,
Carla Manitab Departamento de Doenças Infeciosas, Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, Portugal
,
João Almeida Santosb Departamento de Doenças Infeciosas, Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, PortugalORCID Iconhttps://orcid.org/0000-0002-8564-1098
ORCID Icon,
Sofia Soeirob Departamento de Doenças Infeciosas, Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, Portugal
,
Rita de Sousab Departamento de Doenças Infeciosas, Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, PortugalORCID Iconhttps://orcid.org/0000-0001-6134-6003
ORCID Icon,
Inês Costab Departamento de Doenças Infeciosas, Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, PortugalORCID Iconhttps://orcid.org/0000-0003-2430-0721
ORCID Icon,
Nuno Verdascab Departamento de Doenças Infeciosas, Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, Portugal
,
Raquel Guiomarb Departamento de Doenças Infeciosas, Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, PortugalORCID Iconhttps://orcid.org/0000-0002-4563-6315
ORCID Icon,
Ana Paula Rodriguesa Departamento de Epidemiologia, Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, PortugalORCID Iconhttps://orcid.org/0000-0003-2264-4723
ORCID Icon & on Behalf of ISN2COVID-19 Group show all
Pages 418-424 | Received 04 Jun 2021, Accepted 30 Dec 2021, Published online: 13 Jan 2022

References

  • Statistics Portugal. COVID-19: uma leitura do contexto demográfico e da expressão territorial da pandemia. Lisboa: Statistics Portugal; 2021.
  • ECDC. Data on 14-day notification rate of new COVID-19 cases and deaths. Eur Cent Dis Prev Control. 2021. https://www.ecdc.europa.eu/en/publications-data/data-national-14-day-notification-rate-covid-19
  • Direção-Geral da Saúde. Norma 002/2021 de 30/01/2021. Campanha de Vacinação Contra a COVID-19. Lisboa; 2021.
  • Direção Geral da Saúde. COVID-19 Situação epidemiológica em Portugal. Relatório de situação no 395. Lisboa: Direção-Geral da Saúde; 2021.
  • Direção-Geral da Saúde. Relatório de vacinação. Semana 13; Lisboa: Direção-Geral da Saúde; 2021.
  • Pollán M, Pérez-Gómez B, Pastor-Barriuso R, et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. Lancet. 2020;396(10250):535–544.
  • Valliant R, Dever JA. Survey weights: a step-by-step guide to calculation. 1st ed. College Station, TX: Stata Press; 2018.
  • Rao JNK, Scott AJ. On simple adjustments to Chi-Square tests with sample survey data. Ann Stat. 1987;15:385–397.
  • Kislaya I, Gonçalves P, Barreto M, ISNCOVID-19 Group, et al. Seroprevalence of SARS-CoV-2 infection in Portugal in May–July 2020: results of the first national serological survey (ISNCOVID-19). Acta Med Port. 2021;34(2):87–94.
  • Havers FP, Reed C, Lim T, et al. Seroprevalence of antibodies to SARS-CoV-2 in 10 sites in the United States, March 23-May 12, 2020. JAMA Intern Med. 2020;180(12):1576–1586.
  • Reicher S, Ratzon R, Ben-Sahar S, et al. Nationwide seroprevalence of antibodies against SARS-CoV-2 in Israel. Eur J Epidemiol. 2021;36(7):727–734.
  • Canto e Castro L, Pereira AHG, Ribeiro R, et al. Prevalence of SARS-CoV-2 antibodies after first 6 months of COVID-19 pandemic, Portugal. Emerg Infect Dis. 2021;27(11):2878–2881.
  • Direção-Geral da Saúde. Norma 019/2020 de 26/10/2020 Estratégia Nacional de Testes para SARS-CoV-2 (Atualização a 11/02/2021). Lisboa; 2021.
  • Stringhini S, Wisniak A, Piumatti G, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. Lancet. 2020;396(10247):313–319.
  • Allen JC, Toapanta FR, Chen W, et al. Understanding immunosenescence and its impact on vaccination of older adults. Vaccine. 2020;38(52):8264–8272.
  • Del Giudice G, Goronzy JJ, Grubeck-Loebenstein B, et al. Fighting against a protean enemy: immunosenescence, vaccines, and healthy aging. NPJ Aging Mech Dis. 2018;4:1.
  • Viner RM, Mytton OT, Bonell C, et al. Susceptibility to SARS-CoV-2 infection among children and adolescents compared with adults: a systematic review and meta-analysis. JAMA Pediatr. 2021;175(2):143–156.
  • Bobrovitz N, Arora RK, Cao C, et al. Global seroprevalence of SARS-CoV-2 antibodies: a systematic review and meta-analysis. PLOS One. 2021;16(6):e0252617.
  • Caserotti M, Girardi P, Rubaltelli E, et al. Associations of COVID-19 risk perception with vaccine hesitancy over time for italian residents. Soc Sci Med. 2021;272:113688.
  • Rattay P, Michalski N, Domanska OM, et al. Differences in risk perception, knowledge and protective behaviour regarding COVID-19 by education level among women and men in Germany. Results from the COVID-19 snapshot monitoring (COSMO) study. PLOS One. 2021;16(5):e0251694.
  • Direção-Geral da Saúde. Relatório de vacinação. Semana 17. Lisboa: Direção-Geral da Saúde; 2021.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.